A J Bayer

Summary

Affiliation: Cardiff University
Country: UK

Publications

  1. ncbi request reprint The doctor's duty to the elderly patient in clinical trials
    Antony Bayer
    Department of Geriatric Medicine, University of Wales College of Medicine, Cardiff, UK
    Drugs Aging 20:1087-97. 2003
  2. ncbi request reprint Evaluation of the safety and immunogenicity of synthetic Abeta42 (AN1792) in patients with AD
    A J Bayer
    University Department of Geriatric Medicine, Academic Centre, University of Wales College of Medicine, Llandough Hospital, Penarth Road, Cardiff, South Glamorgan, CF64 2XX, UK
    Neurology 64:94-101. 2005
  3. ncbi request reprint Age and gender bias in statin trials
    S Bandyopadhyay
    University Department of Geriatric Medicine, Llandough Hospital, Penarth, UK
    QJM 94:127-32. 2001
  4. ncbi request reprint Abeta species removal after abeta42 immunization
    James A R Nicoll
    Division of Clinical Neurosciences, School of Medicine, University of Southampton, Southampton, UK
    J Neuropathol Exp Neurol 65:1040-8. 2006
  5. ncbi request reprint Safety and tolerability of once-daily versus twice-daily memantine: a randomised, double-blind study in moderate to severe Alzheimer's disease
    Roy W Jones
    Research Institute for the Care of the Elderly RICE, Bath, UK
    Int J Geriatr Psychiatry 22:258-62. 2007
  6. ncbi request reprint Phasic visual alertness in Alzheimer's disease and ageing
    Andrea Tales
    School of Psychology, Cardiff University, Cardiff CF11 3YG, Wales, UK
    Neuroreport 13:2557-60. 2002

Detail Information

Publications6

  1. ncbi request reprint The doctor's duty to the elderly patient in clinical trials
    Antony Bayer
    Department of Geriatric Medicine, University of Wales College of Medicine, Cardiff, UK
    Drugs Aging 20:1087-97. 2003
    ..Those with cognitive impairment and the institutionalised are vulnerable to exploitation and require special consideration and management...
  2. ncbi request reprint Evaluation of the safety and immunogenicity of synthetic Abeta42 (AN1792) in patients with AD
    A J Bayer
    University Department of Geriatric Medicine, Academic Centre, University of Wales College of Medicine, Llandough Hospital, Penarth Road, Cardiff, South Glamorgan, CF64 2XX, UK
    Neurology 64:94-101. 2005
    ..This phase 1 study evaluated the safety, tolerability, and immunogenicity of AN1792 (human aggregated Abeta42) in patients with mild to moderate AD...
  3. ncbi request reprint Age and gender bias in statin trials
    S Bandyopadhyay
    University Department of Geriatric Medicine, Llandough Hospital, Penarth, UK
    QJM 94:127-32. 2001
    ..Statin drug trials have suffered from age and gender bias, having been mainly conducted in middle-aged male populations. The extrapolation of evidence from these trials to older people and women needs further evaluation...
  4. ncbi request reprint Abeta species removal after abeta42 immunization
    James A R Nicoll
    Division of Clinical Neurosciences, School of Medicine, University of Southampton, Southampton, UK
    J Neuropathol Exp Neurol 65:1040-8. 2006
    ..Abeta immunotherapy can clear all Abeta species from the cortex. However, if it is to be used for treatment of established Alzheimer disease, then the residual tau pathology and cerebral amyloid angiopathy require further study...
  5. ncbi request reprint Safety and tolerability of once-daily versus twice-daily memantine: a randomised, double-blind study in moderate to severe Alzheimer's disease
    Roy W Jones
    Research Institute for the Care of the Elderly RICE, Bath, UK
    Int J Geriatr Psychiatry 22:258-62. 2007
    ..To assess the safety and tolerability of three different dosing schedules of memantine in patients with moderate to severe Alzheimer's disease (AD)...
  6. ncbi request reprint Phasic visual alertness in Alzheimer's disease and ageing
    Andrea Tales
    School of Psychology, Cardiff University, Cardiff CF11 3YG, Wales, UK
    Neuroreport 13:2557-60. 2002
    ..This marked inability to increase phasic alertness in AD may contribute to the everyday problems faced by these patients, and may provide a simple tool to aid diagnosis and disease progression...